Skip to Content
Coefficient Giving
Funds

Science and Global Health R&D

We support research and development into new tools to improve global health.

Contents

About the Fund

Team

Partners

Interested in learning more or joining the fund? Reach out to partnerwithus@coefficientgiving.org.

Health technologies like vaccines and drugs save millions of lives around the world. Yet many cures remain undiscovered. Government and private sector funders do not always prioritize research and development (R&D) that could help the most people live long and healthy lives.

Diseases like tuberculosis, malaria, and rheumatic heart disease that primarily affect the world’s poorest people receive much less R&D spending relative to their health burdens than diseases affecting the wealthy. High-risk, transformational science often goes unfunded, too. 

We are particularly interested in supporting products or fields where progress has stalled, where additional resources could accelerate breakthrough discoveries and new tools for global health.

We have supported scientific research for human health since 2016, expanding our work in global health R&D in 2023. Our work includes:

Request for Proposals

RFP on Generic Drug Repurposing

Coefficient Giving is launching a Request for Proposals to fund rigorous investigations of repurposed generic drugs for high-burden yet neglected diseases. We are seeking proposals to move promising candidates toward clinical evidence of efficacy — leveraging the speed, cost, and access advantages that repurposing offers to deliver new treatment options for patients who cannot wait for the next generation of drug discovery.

Read more

Research & Updates

  • Some diseases that kill many people receive very few resources for the development of diagnostics, treatments, and vaccines. In relative terms, R&D funding varies by 10 times or more across diseases, often without good reason. This suggests that science funders could find high-impact opportunities by targeting the most neglected diseases.

    Read more

  • In October 2024, our longtime grantee David Baker won the Nobel Prize in Chemistry for his groundbreaking work in protein design. We wanted to take the opportunity to highlight his work and some of its practical applications, such as enabling better vaccines.

    Read more

  • We spotlight five grantees whose work exemplifies our approach to hits-based giving in scientific research. These examples illustrate different aspects of our science funding strategy and represent some of the project types we aim to support.

    Read more

330+

grants made

$550+

million given

30+

social investments made

$90+

million in social investments